



1646  
Box 582  
#33  
JP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Daniel Caput et al.

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

Serial No.: 09/077,817

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service addressed to:

Filed: September 14, 1998

Group Art Unit: 1646

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Examiner: Basi, N.

For: Purified Polypeptides Having IL-13  
Receptor Activity

Name

Date

*Bernadine S. Blair*  
*May 9, 2003*

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
MAY 14 2003  
TECH CENTER 1600/2900

Dear Sir:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed April 9, 2003 (Paper No. 32), set a one-month shortened statutory period for response expiring May 9, 2003. This response is therefore timely filed.

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed April 9, 2003 (Paper No. 32), enclosed is a substitute computer readable disk. The enclosed disk contains the Sequence Listing as filed with the Amendment dated December 19, 2002, and contains no new matter.

Respectfully submitted,

Date:

*May 9, 2003*  
Address:  
Sanofi-Synthelabo Inc.  
9 Great Valley Parkway  
Malvern, PA 19355  
Tele: (610) 889-6338  
Facsimile: (610) 889-8799

*Paul E. Dupont*  
Paul E. Dupont  
Reg. No. 27,438